Publications by authors named "R Ria"
Background: Daratumumab-refractory multiple myeloma (Dara-R MM) presents a significant treatment challenge. This study aimed to evaluate the efficacy and survival outcomes of elotuzumab, pomalidomide, and dexamethasone (EloPd) in a large, real-world cohort of patients with Dara-R MM, with particular focus on progression-free survival (PFS) and overall survival (OS).
Materials And Methods: This retrospective analysis included 247 Dara-R MM patients treated with EloPd.
Two-year follow-up after drug desensitization in mucopolysaccharidosis.
Orphanet J Rare Dis
December 2024
Background: Mucopolysaccharidosis (MPS) type 1 S and type 2 are rare lysosomal storage disorders characterized by impaired enzyme production, resulting in glycosaminoglycans accumulation within lysosomes. Enzyme Replacement Therapy (ERT) with laronidase and idursulfase are first line treatments, respectively. However, infusion-related hypersensitivity reactions (HR) may lead to ERT discontinuation.
View Article and Find Full Text PDFArticle Synopsis
- Eosinophilic granulomatous polyangiitis (EGPA) is a rare autoimmune disease marked by inflammation and high eosinophil levels, traditionally treated with corticosteroids and immunosuppressants, which can have serious side effects.
- A systematic review and meta-analysis of eight studies with 396 EGPA patients found that benralizumab, a biologic agent targeting the interleukin-5 receptor, significantly reduced oral corticosteroid use and led to remission in over half the patients.
- The study concluded that benralizumab is an effective and well-tolerated treatment for EGPA, recommending further large-scale research to assess its long-term efficacy and safety.
Immunoglobulin (Ig) replacement therapy (IgRT) consists of the administration of low-dose human polyclonal Igs for the treatment of primary and secondary hypogammaglobulinemia that are associated with recurrent infections and immune dysfunction. IgRT restores physiological antibody levels and induces an immunomodulatory effect by strengthening immune effector cells, thus reducing infections. Here, we describe the pharmacology of different Ig formulations with a particular focus on their mechanism of action as low-dose IgRT, including the direct anti-microbial effect and the immunomodulatory function.
View Article and Find Full Text PDFMultiple myeloma (MM) is a hematologic malignancy characterized by abnormal plasma cell proliferation in the bone marrow. Recent advancements in anti-CD38 monoclonal antibody therapies, such as daratumumab and isatuximab, have significantly improved MM patient survival. However, the lack of predictive factors of response to these therapies remains a challenge.
View Article and Find Full Text PDF